EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
ExpreS2ion Biotechnologies
Vice President - Business Development
ExpreSion Biotechnologies protein expression system ExpreS is an important protein expression tool in the scientists tool box for protein expression The ExpreS platform has demonstrated in many instances its usefulness in RD with several ExpreSmade proteins having now been crystallized
Articles
Are We Ready to Ship Billions of COVID Vaccines Worldwide?
Theres no denying it has been a year of immense difficulty and disruptionMany now look forward to and the muchanticipated prospect of COVID vaccines as the gateway to global recovery Naturally as one of the the worlds leading logistics companies FedEx has an important role to play in vaccine shipment
Research Insights
Stochastic ordering of complexoform protein assembly by genetic circuits
Topdown proteomics has enabled the elucidation of heterogeneous protein complexes with different cofactors posttranslational modifications and protein membership This heterogeneity is believed to play a previously unknown role in cellular processes
Case Studies
Isolation Technology: Case Study
A customer active in the hormone production recently searched an appropriate solution for grinding material and clean packaging after the filtering and drying process The following requirements had to be met To provide a safe barrier between the operator and the active drug substance to provide both operator and product protect
Techno Trends
Janssen's Novel Bispecific Antibodies TALVEY® (talquetamab) and TECVAYLI® (teclistamab) Shows Positive CHMP Opinions for Refractory Multiple Myeloma Treatment
Janssen has received positive opinions for two novel talquetamab and teclistamab bispecific antibodies for the trreatment of patients with Relapsed and Refractory Multiple Myeloma
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
QSAR - Changing the Landscape of Antidiabetic Drug Discovery
Smriti Sharma Bhatia is an associate professor of chemistry at Miranda House, University of Delhi, India. Her academic and research interests include Computational chemistry and drug design. Currently, her research group is focused on the design of oral drug formulations for Type 2 diabetes mellitus. She is a popular science communicator.
Syringe-like Bacterial Nanomachine Emerges as Potential Therapeutics Delivery Device
I am Chanchal Kumawat. I started my journey in science as Ph.D. student at Regional Centre for Biotechnology and continued as postdoctoral fellow at Max Perutz labs, Austria. I enjoyed making scientific discoveries in the laboratory and now, enjoy communicating it as a science writer.
Green Synthesis of Metallic Nanoparticles
Ms. Aishwarya Jain is a distinguished pharmaceutical scientist and academician with over six years of experience in pharmaceutical sciences. Currently serving as an Assistant Professor at Sinhgad College of Pharmacy, Vadgaon (Bk), Pune, she has carved a niche for herself in the domains of nanotechnology, green synthesis, and pharmaceutical innovation.
A recipient of 65+ prestigious national and international awards, including the Bharat Shiksha Gaurav Puraskar and the Women Empowerment Award, Ms. Jain is recognised as one of the leading voices in pharmaceutical education and research. Her scholarly contributions span numerous books, book chapters, and high-impact research articles published in top-tier journals indexed in SCOPUS and Web of Science.
Renowned for her commitment to academic excellence and research integrity, she also plays an active role as an editorial board member and peer reviewer for reputed scientific journals and publishing houses. Her work exemplifies a seamless blend of academic rigor and innovative thinking, particularly in green nanotechnology and sustainable drug development.
Driven by a vision to advance pharmaceutical science for global health impact, Ms. Aishwarya continues to inspire through her interdisciplinary collaborations, cutting-edge research, and passionate teaching.
Unleashing the Power of Data, Collaboration, and Innovation in Drug Development
Pooja is a Healthcare & Life Sciences leader at Thoughtworks with over 15 years of experience in technology consulting. Specialising in AI-driven solutions and strategic initiatives that enhance drug discovery and patient care, she has a unique background in both bioinformatics and product management. Passionate about navigating ambiguity and solving customer problems, Pooja’s current focus is on leveraging emerging technologies to accelerate innovation in healthcare and life sciences.
New Paradigm in Combination Therapy of siRNA with Chemotherapeutic Drugs towards Cancer Targeting
Ruchi is currently designated as Associate Professor, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi-221005, (U.P.), India. Her area of research is nanotechnology based drug delivery systems for targeted delivery of drugs and addressing issues related to conventional dosage forms like poor bioavailability, solubility, higher dose. She has more than 20 publications in international scientific journals including original research articles, reviews and book chapters. e-mail ID – rchawla.phe@iitbhu.ac.in
Krishan Kumar is currently pursuing Ph.D. in Pharmaceutics at Department of Pharmaceutical Engineering, IIT BHU. His research focus on targeted and controlled drug delivery approaches in Nano-therapeutics. He has authored or co-authored 8 publications in international scientific journals in his fields of expertise. He has 2 years 8 months R&D experience in Reckitt Benckiser (India) Ltd. e-mail ID- krishaniskrishan@gmail.com
Varsha Rani is currently Ph.D. research scholar at Department of Pharmaceutical Engineering and Technology, IIT (BHU) Varanasi, India. She is involved in research area focussed on nanocarriers for brain targeted drug delivery system. She has contributed to ten publications including research article, review article and book chapter in reputed scientific journals. She has also done industrial training from Evonik India Pvt. Ltd, Mumbai, India. e-mail ID – varsharani.rs.phe17@itbhu.ac.in
Mohini Mishra is a PhD research scholar at Indian Institute of Technology BHU, Varanasi, India and his area of research is focused on the development of nanoparticulate-based targeted drug delivery systems against BHneurodegenerative diseases. She has authored and co- authored nine publications in international scientific journals and three are in the pipeline. e-mail ID- mohini.mishra0203@gmail.com
press releasesRead more...
Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines
Astellas Pharma Inc TSE President and CEO Naoki Okamura Astellas today announced that it has reached an agreement with the US government that reflects our commitment to patient access affordability
DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform
DUALITYBIO Inc HKEX DualityBio or the Company today announced that it has entered into a collaboration and license agreement with Genentech a member of the Roche Group to develop nextgeneration
Data4Life and Monash Health Announce Strategic Collaboration to Advance Clinical Research
Monash Health the largest public health service in Victoria Australia has signed a Memorandum of Understanding MoU with DataLife an international nonprofit digital health organization funded by the Hasso
HKBU hosts inaugural International Symposium on Innovation and R&D in Traditional Chinese Medicine to promote modernisation, internationalisation and research translation in Chinese medicine
Hong Kong Baptist University HKBU InnoHK Centre for Chinese Herbal Medicine Drug Development CDD coorganised the inaugural International Symposium on Innovation and RD in Traditional
11th Edition Medical Device Project and Portfolio Management
Medical device organizations are under increasing pressure to deliver more innovation with fewer resources while navigating regulatory complexity rising development costs portfolio congestion and growing demands
Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases
Eli Lilly and Company NYSE LLY and Merida Biosciences Inc Merida a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases today announced a definitive agreement for Lilly to acquire Merida
EventsRead more...
03 - 05
Sep 20265th MENA Congress for Rare Diseases 2026
Beach Rotana Hotel, Abu Dhabi,...
14 - 15
Sep 202616th American DDF Summit
Omni Boston Hotel at the Seapo...
14 - 16
Sep 202615 - 17
Sep 2026COPD Drug Development Summit 2026
Street, Boston, MA 02210, USA
21 - 23
Sep 2026Cell & Gene Therapy World Conference
Miami, Florida, USA
21 - 23
Sep 2026Cancer R&D World Conference
Hilton Garden Inn Miami Dolphi...
22 - 23
Sep 2026PDA Advanced Parenteral Therapeutics & Quality Summit
Illume Hotel Taipei, Taiwan
28 - 01
Sep 2026Discovery on Target 2026
Boston, MA, USA
LATEST NEWSRead more...
HUTCHMED Announces Approval of ATLED® (Fanregratinib) for FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
HUTCHMED has received conditional approval from Chinas National Medical Products Administration NMPA for ATLED fanregratinib to treat adults with advanced metastatic or unresectable intrahepatic cholangiocarcinoma ICC with FGFR fusion or rearrangement who have previously received systemic therapy
Osivax Enters into Collaboration with GC Biopharma to Develop Next-Generation Influenza Vaccine
Osivax and GC Biopharma have entered into a strategic collaboration to develop and commercialise a nextgeneration seasonal influenza vaccine designed to provide broader and more durable protection against a range of influenza strains
Cipla Enters into Agreement with SBP Group for HER2 bispecific ADC TQB2102
Cipla and Sino Biopharmaceutical SBP Group have entered into an exclusive licensing and supply agreement for Rolditamig Deuderuxtecan also known as TQB a HERtargeted bispecific antibodydrug conjugate ADC being developed for the treatment of cancer
Jazz Pharmaceuticals Announces Approval of Ziihera Regimens for Advanced HER2-Positive Gastroesophageal Cancer
Jazz Pharmaceuticals has announced that the US Food and Drug Administration FDA has approved two Ziihera zanidatamabhriibased treatment regimens for the firstline treatment of adults with unresectable
BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients
BioCryst Pharmaceuticals has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORLADEYO berotralstat for the prevention of hereditary angioedema HAE attacks in children aged to under years
Takeda Receives Approval for ORZEYFUL (oveporexton) to Treat Narcolepsy Type 1
Takeda has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORZEYFUL oveporexton for the treatment of narcolepsy type NT a form of narcolepsy associated with cataplexy in adults